Weekly Recap: Canada Plasma control and 61% Alzheimer’s progression cut
Grifols, S.A. Sponsored ADR Class B (BME:GRF) has taken full management control of Canada Plasma Inc. to remedy Health Canada—flagged regulatory issues while reporting AMBAR real-world data showing a 61% reduction in disease progression for treated mild-to-moderate Alzheimer’s patients.Previous Wee…